Brain natriuretic peptide (BNP) affects the regulation of myocardial metabolism through the production of cGMP and these effects may be altered by cardiac hypertrophy. We tested the hypothesis that BNP would cause decreased metabolism and function in the heart and cardiac myocytes by increasing cGMP and that these effects would be disrupted after thyroxine-induced cardiac hypertrophy (T4). Open-chest control and T4 rabbits were instrumented to determine local effects of epicardial BNP (10-3 M). Function of isolated cardiac myocytes was examined with BNP (10-8-10-7 M) with or without KT5823 (10-6 M, cGMP protein kinase inhibitor). Cyclic GMP levels were measured in myocytes. In open-chest controls, O2 consumption was reduced in the BNP area of the subepicardium (6.6 ± 1.3 ml O2/min/100 g versus 8.9 ± 1.4 ml O2/min/100 g) and subendocardium (9.4 ± 1.3 versus 11.3 ± 0.99). In T4 animals, functional and metabolic rates were higher than controls, but there was no difference between BNP-treated and untreated areas. In isolated control myocytes, BNP (10-7 M) reduced percent shortening (PSH) from 6.5 ± 0.6 to 4.3 ± 0.4%. With KT5823 there was no effect of BNP on PSH. In T4 myocytes, BNP had no effect on PSH. In control myocytes, BNP caused cGMP levels to rise from 279 ± 8 to 584 ± 14 fmol/105 cells. In T4 myocytes, baseline cGMP levels were lower (117 ± 2 l) and were not significantly increased by BNP. Thus, BNP caused decreased metabolism and function while increasing cGMP in control. These effects were lost after T4 due to lack of cGMP production. These data indicated that the effects of BNP on heart function operated through a cGMP-dependent mechanism, and that this mechanism was disrupted in T4-induced cardiac hypertrophy.
ASJC Scopus subject areas
- Cellular and Molecular Neuroscience
- Cardiac hypertrophy
- Cardiac myocyte function
- Cyclic GMP
- Myocardial oxygen consumption
- Natriuretic peptides